LISAvienna: The March edition of our newsletter has been published

It's newsletter season at LISAvienna, and we're thrilled to share a few updates from life sciences research institutions in Vienna, including CeMM, IMBA, MedUni Vienna, and Uni Vienna. Additionally, we're spotlighting exciting developments in the business world from companies like ADvantage Therapeutics, BlueSky Immunotherapies, Cebina, Cellectric Biosciences, Myllia, OncoOne, piur imaging, Technoclone, UpNano, Valneva and many others.

Furthermore, we're providing a comprehensive overview of funding opportunities and upcoming events where you can connect with LISAvienna or participate at reduced rates. A special feature of this edition is an insightful article highlighting the Vienna Business Agency’s funding programs aimed at bolstering Vienna's position as a leading metropolis of health innovation.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.